Lupus Market Research Report by Type (Systemic Lupus Erythematosus, Neonatal Lupus, Others), Treatment (NSAIDS, Corticosteroid, Antimalarial Drug, Biologics, Other), End User (Hospital & Clinics, Diagnostic Laboratories, Others), and Region-Forecast till 2032

Table of Contents

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

Chapter 6. Global Lupus Market, by Type

6.1 Introduction

6.2 Systemic Lupus Erythematosus

Market Estimates & Forecast, by Region, 2022–2030

Market Estimates & Forecast, by Country, 2022–2030

6.3 Cutaneous Lupus Erythematosus

Market Estimates & Forecast, by Region, 2022–2030

Market Estimates & Forecast, by Country, 2022–2030

6.4 Drug-Induced Lupus Erythematosus

Market Estimates & Forecast, by Region, 2022–2030

Market Estimates & Forecast, by Country, 2022–2030

6.5 Neonatal lupus

Market Estimates & Forecast, by Region, 2022–2030

Market Estimates & Forecast, by Country, 2022–2030

Chapter 7. Global Lupus Market, by Treatment

7.1 Introduction

7.2 Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)

Market Estimates & Forecast, by Region, 2022–2030

Market Estimates & Forecast, by Country, 2022–2030

7.3 Antimalarial Drugs

Market Estimates & Forecast, by Region, 2022–2030

Market Estimates & Forecast, by Country, 2022–2030

7.4 Corticosteroids

Market Estimates & Forecast, by Region, 2022–2030

Market Estimates & Forecast, by Country, 2022–2030

7.5 Immunosuppressants

Market Estimates & Forecast, by Region, 2022–2030

Market Estimates & Forecast, by Country, 2022–2030

7.6 Biologics

Market Estimates & Forecast, by Region, 2022–2030

Market Estimates & Forecast, by Country, 2022–2030

7.7 Others

Chapter 8. Global Lupus Market, by End User

8.1 Introduction

8.2 Hospital & Clinics

Market Estimates & Forecast, by Region, 2022–2030

Market Estimates & Forecast, by Country, 2022–2030

8.3 Diagnostic Laboratories

Market Estimates & Forecast, by Region, 2022–2030

Market Estimates & Forecast, by Country, 2022–2030

8.4 Others

Chapter 9. Global Lupus Market, by Region

9.1 Introduction

9.2 Americas

9.2.1 North America

9.2.1.1 US

9.2.1.2 Canada

9.2.2 South America

9.3 Europe

9.3.1 Western Europe

9.3.1.1 Germany

9.3.1.2 France

9.3.1.3 Italy

9.3.1.4 Spain

9.3.1.5 UK

9.3.1.6 Rest of Western Europe

9.3.2 Eastern Europe

9.4 Asia-Pacific

9.4.1 Japan

9.4.2 China

9.4.3 India

9.4.4 Australia

9.4.5 South Korea

9.4.6 Rest of Asia-Pacific

9.5 Middle East & Africa

9.5.1 Middle East

9.5.2 Africa

Chapter 10. Company Landscape

10.1 Introduction

10.2 Market Share Analysis

10.3 Key Development & Strategies

Chapter 11. Company Profiles

11.1 Aurinia Pharmaceuticals Inc.

11.1.1 Company Overview

11.1.2 Treatment Overview

11.1.3 Financials Overview

11.1.4 Key Developments

11.1.5 SWOT Analysis

11.2 Bristol-Myers Squibb Company

11.2.1 Company Overview

11.2.2 Treatment Overview

11.2.3 Financial Overview

11.2.4 Key Developments

11.2.5 SWOT Analysis

11.3 Cadila Healthcare

11.3.1 Company Overview

11.3.2 Treatment Overview

11.3.3 Financial Overview

11.3.4 Key Development

11.3.5 SWOT Analysis

11.4 GlaxoSmithKline plc

11.4.1 Company Overview

11.4.2 Treatment Overview

11.4.3 Financial Overview

11.4.4 Key Development

11.4.5 SWOT Analysis

11.5 Mylan N.V.

11.5.1 Company Overview

11.5.2 Treatment Overview

11.5.3 Financial overview

11.5.4 Key Developments

11.5.5 SWOT Analysis

11.6 F. Hoffmann-La Roche AG

11.6.1 Company Overview

11.6.2 Treatment Overview

11.6.3 Financial Overview

11.6.4 Key Developments

11.6.5 SWOT Analysis

11.7 Pfizer, Inc.

11.7.1 Overview

11.7.2 Treatment Overview

11.7.3 Financial Overview

11.7.4 Key Developments

11.7.5 SWOT Analysis

11.8 Sanofi

11.8.1 Overview

11.8.2 Treatment Overview

11.8.3 Financials

11.8.4 Key Developments

11.8.5 SWOT Analysis

11.9 Lycera Corporation

11.9.1 Overview

11.9.2 Treatment Overview

11.9.3 Financials

11.9.4 Key Developments

11.9.5 SWOT Analysis

11.10 Merck KGaA

11.10.1 Overview

11.10.2 Treatment Overview

11.10.3 Financials

11.10.4 Key Developments

11.10.5 SWOT Analysis

11.11 Eli Lily and Company

11.11.1 Overview

11.11.2 Treatment Overview

11.11.3 Financials

11.11.4 Key Developments

11.11.5 SWOT Analysis

11.12 Others

Chapter 12 MRFR Conclusion

12.1 Key Findings

12.1.1 From CEO’s Viewpoint

12.1.2 Unmet Needs of the Market

12.2 Key Companies to Watch

12.3 Predictions for the Lupus Industry

Chapter 13. Appendix

LIST OF TABLES

Table 1 Global Lupus Market Synopsis, 2022–2030

Table 2 Global Lupus Market Estimates and Forecast, 2022–2030

(USD Million)

Table 3 Global Lupus Market, by Region, 2022–2030 (USD Million)

Table 4 Global Lupus Market, by Type, 2022–2030 (USD Million)

Table 5 Global Lupus Market, by Treatment, 2022–2030 (USD Million)

Table 6 Global Lupus Market, by End User, 2022–2030 (USD Million)

Table 7 North America: Lupus Market, by Type, 2022–2030 (USD Million)

Table 8 North America: Lupus Market, by Treatment, 2022–2030 (USD Million)

Table 9 North America: Lupus Market, by End User, 2022–2030 (USD Million)

Table 10 US: Lupus Market, by Type, 2022–2030 (USD Million)

Table 11 US: Lupus Market, by Treatment, 2022–2030 (USD Million)

Table 12 US: Lupus Market, by End User, 2022–2030 (USD Million)

Table 13 Canada: Lupus Market, by Type, 2022–2030 (USD Million)

Table 14 Canada: Lupus Market, by Treatment, 2022–2030 (USD Million)

Table 15 Canada: Lupus Market, by End User, 2022–2030 (USD Million)

Table 16 South America: Lupus Market, by Type, 2022–2030

(USD Million)

Table 17 South America: Lupus Market, by Treatment, 2022–2030

(USD Million)

Table 18 South America: Lupus Market, by End User, 2022–2030

(USD Million)

Table 19 Europe: Lupus Market, by Type, 2022–2030 (USD Million)

Table 20 Europe: Lupus Market, by Treatment, 2022–2030 (USD Million)

Table 21 Europe: Lupus Market, by End User, 2022–2030 (USD Million)

Table 22 Western Europe: Lupus Market, by Type, 2022–2030 (USD Million)

Table 23 Western Europe: Lupus Market, by Treatment, 2022–2030 (USD Million)

Table 24 Western Europe: Lupus Market, by End User, 2022–2030 (USD Million)

Table 25 Eastern Europe: Lupus Market, by Type, 2022–2030 (USD Million)

Table 26 Eastern Europe: Lupus Market, by Treatment, 2022–2030 (USD Million)

Table 27 Eastern Europe: Lupus Market, by End User, 2022–2030 (USD Million)

Table 28 Asia-Pacific: Lupus Market, by Type, 2022–2030 (USD Million)

Table 29 Asia-Pacific: Lupus Market, by Treatment, 2022–2030

(USD Million)

Table 30 Asia-Pacific: Lupus Market, by End User, 2022–2030 (USD

Million)

Table 31 Middle East & Africa: Lupus Market, by Type, 2022–2030 (USD Million)

Table 32 Middle East & Africa: Lupus Market, by Treatment, 2022–2030 (USD Million)

Table 33 Middle East & Africa: Lupus Market, by End User, 2022–2030 (USD Million)

LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation for Global Lupus Market

Figure 3 Segmentation Market Dynamics for Global Lupus Market

Figure 4 Global Lupus Market Share, by Type, 2022

Figure 5 Global Lupus Market Share, by Treatment, 2022

Figure 6 Global Lupus Market Share, by End User, 2022

Figure 7 Global Lupus Market Share, by Region, 2022

Figure 8 North America: Lupus Market Share, by Country, 2022

Figure 9 Europe: Lupus Market Share, by Country, 2022

Figure 10 Asia-Pacific: Lupus Market Share, by Country, 2022

Figure 11 Middle East & Africa: Lupus Market Share, by Country, 201

Figure 12 Global Lupus Market: Company Share Analysis, 2022 (%)

Figure 13 Aurinia Pharmaceuticals Inc.: Key Financials

Figure 14 Aurinia Pharmaceuticals Inc.: Segmental Revenue

Figure 15 Aurinia Pharmaceuticals Inc.: Geographical Revenue

Figure 16 Bristol-Myers Squibb Company: Key Financials

Figure 17 Bristol-Myers Squibb Company: Segmental Revenue

Figure 18 Bristol-Myers Squibb Company: Geographical Revenue

Figure 19 Cadila Healthcare: Key Financials

Figure 20 Cadila Healthcare: Segmental Revenue

Figure 21 Cadila Healthcare: Geographical Revenue

Figure 22 GlaxoSmithKline plc : Key Financials

Figure 23 GlaxoSmithKline plc: Segmental Revenue

Figure 24 GlaxoSmithKline plc : Geographical Revenue

Figure 25 Mylan N.V: Key Financials

Figure 26 Mylan N.V: Segmental Revenue

Figure 27 Mylan N.V. Geographical Revenue

Figure 28 F. Hoffmann-La Roche AG: Key Financials

Figure 29 F. Hoffmann-La Roche AG: Segmental Revenue

Figure 30 F. Hoffmann-La Roche AG: Geographical Revenue

Figure 31 Pfizer, Inc.: Key Financials

Figure 32 Pfizer, Inc.: Segmental Revenue

Figure 33 Pfizer, Inc.: Geographical Revenue

Figure 34 Sanofi: Key Financials

Figure 35 Sanofi: Segmental Revenue

Figure 36 Sanofi: Geographical Revenue

Figure 37 Lycera Corporation: Key Financials

Figure 38 Lycera Corporation: Segmental Revenue

Figure 39 Lycera Corporation: Geographical Revenue

Figure 40 Merck KGaA: Key Financials

Figure 41 Merck KGaA : Segmental Revenue

Figure 42 Merck KGaA: Geographical Revenue

Figure 43 Eli Lily and Company: Key Financials

Figure 44 Eli Lily and Company: Segmental Revenue

Figure 45 Eli Lily and Company: Geographical Revenue

Figure 46 Norgen Biotek Corp.: Key Financials

Figure 47 Norgen Biotek Corp.: Segmental Revenue

Figure 48 Norgen Biotek Corp.: Geographical Revenue